Revelation Biosciences, Inc. announced that The Nasdaq Stock Market LLC formally notified the company of its continued listing and trading on Nasdaq. This notification confirms that REVB common stock is now in compliance with all requirements for continued listing. This follows a previous conditional approval granted by the Nasdaq Hearings Panel.
The company's CEO, James Rolke, stated that maintaining the Nasdaq listing is crucial for stockholder liquidity and access to capital. He also emphasized its importance for attracting and retaining talent necessary to advance the company's research and drive its growth. This approval removes a significant regulatory overhang for the company.
This positive development comes after Revelation Biosciences announced the commencement of its PRIME Phase 1b clinical study in patients with Stage 3 and 4 Chronic Kidney Disease on January 21, 2025. The company is focused on accelerating its growth and building a robust, high-value enterprise, with the Nasdaq listing providing a stable platform for these efforts.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.